Table 7.

CTRP3 and Inflammation

Model	Reference	Type of treatment	Effect
Human primary colonic lamina propria fibroblasts (CLPF)	Hofmann et al. 2011 (21)	Recombinant CTRP-3 (high-five insect cells)	Significantly and dose-dependently reduced LPS-induced IL-8 secretion in CLPF within 8 hours after LPS exposure, whereas LPS-induced IL-6 and TNF release was not affected. CTRP-3 inhibited TGF-β production and the expression of CTGF and collagen I in CLPF, whereas collagen III expression remained unchanged (21)
Primary human monocytes	Kopp et al. 2010 (30)	1 μg/mL recombinant full length CTRP3 (H5 insect cells)	Suppressed LPS-induced MIF & CCL4 release in lean subjects, and MCP-1 in monocytes from both diabetic and leans subjects. Prevents Lauric acid induced release of IL-6 and TNF
Primary human monocytes	Kopp et al. 2010 (31)	1 μg/mL recombinant full length CTRP3 (H5 insect cells)	↓ LPS-induced secretion of IL-6 in monocytes from control but not T2D. CTRP3 did not significantly affect TNF secretion
Adipocyte (3T3-L1)	Li et al. 2014 (38)	Recombinant CTRP3 (uncited origin)	Decreased TNF and IL6 secretion in insulin resistant 3T3-L1A
Transgenic CTRP3 overexpression and CTRP3 knockout	Petersen et al. 2016 (48)	Response to sublethal dose of LPS challenge	No effect on IL-1β, IL-6, TNF-α, or MIP-2 induction
LPS (1 μg i.p.) into male mice +/− CTRP3	Schmid et al. 2014 (60)	Recombinant CTRP-3 (H5 insect cells)	Intraperitoneal injection (but not IV) injection of CTRP-3 significantly reduced LPS-induced IL-6 and levels MIP-2
16 patients diagnosed with IgA nephropathy (IgAN) compared to 12 controls	Zhang et al. 2016 (86)		CTRP3 levels were lower in patients with IgAN (TGF-B and IL-6 levels were elevated in the patients)
THP-1 (human—acute monocytic leukemia cell line)	Weigert et al. 2005 (70)	1 μg/mL recombinant full length CTRP3 (H5 insect cells)	Suppressed LPS induced: IL-6 and TNF expression and secretion